Postexposure Efficacy of Recombinant Vesicular Stomatitis Virus Vectors Against High and Low Doses of Marburg Virus Variant Angola in Nonhuman Primates

Courtney Woolsey; Joan B. Geisbert; Demetrius Matassov; Krystle N. Agans; Viktoriya Borisevich; Robert W. Cross; Daniel J. Deer; Karla A. Fenton; John H. Eldridge; Chad E. Mire; Thomas W. Geisbert

doi:10.1093/infdis/jiy293

Postexposure Efficacy of Recombinant Vesicular Stomatitis Virus Vectors Against High and Low Doses of Marburg Virus Variant Angola in Nonhuman Primates

Courtney Woolsey, Joan B. Geisbert, Demetrius Matassov, Krystle N. Agans, Viktoriya Borisevich, Robert W. Cross, Daniel J. Deer, Karla A. Fenton, John H. Eldridge, Chad E. Mire, Thomas W. Geisbert

Microbiology And Immunology

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

A recombinant vesicular stomatitis virus (rVSV) expressing the Marburg virus (MARV) Musoke variant glycoprotein fully protects macaques against 2 MARV variants and Ravn virus as a preventive vaccine and MARV variant Musoke as a postexposure treatment. To evaluate postexposure efficacy against the most pathogenic MARV variant, Angola, we engineered rVSVs expressing homologous Angola glycoprotein. Macaques were challenged with high or low doses of variant Angola and treated 20-30 minutes after exposure. A total of 25% and 60%-75% of treated macaques survived the high-dose and low-dose challenges, respectively. The more rapid disease progression of variant Angola versus variant Musoke may account for the incomplete protection observed.

Original language	English (US)
Pages (from-to)	S582-S587
Journal	Journal of Infectious Diseases
Volume	218
DOIs	https://doi.org/10.1093/infdis/jiy293
State	Published - Nov 22 2018

Keywords

Angola
Marburg virus
Musoke
filovirus
recombinant vesicular stomatitis virus
treatment.
vaccine

ASJC Scopus subject areas

General Medicine

Access to Document

10.1093/infdis/jiy293

Cite this

Woolsey, C., Geisbert, J. B., Matassov, D., Agans, K. N., Borisevich, V., Cross, R. W., Deer, D. J., Fenton, K. A., Eldridge, J. H., Mire, C. E., & Geisbert, T. W. (2018). Postexposure Efficacy of Recombinant Vesicular Stomatitis Virus Vectors Against High and Low Doses of Marburg Virus Variant Angola in Nonhuman Primates. Journal of Infectious Diseases, 218, S582-S587. https://doi.org/10.1093/infdis/jiy293

Woolsey, C, Geisbert, JB, Matassov, D, Agans, KN, Borisevich, V, Cross, RW, Deer, DJ, Fenton, KA, Eldridge, JH, Mire, CE & Geisbert, TW 2018, 'Postexposure Efficacy of Recombinant Vesicular Stomatitis Virus Vectors Against High and Low Doses of Marburg Virus Variant Angola in Nonhuman Primates', Journal of Infectious Diseases, vol. 218, pp. S582-S587. https://doi.org/10.1093/infdis/jiy293

@article{85006f6c511f4a03990541272cdd6d9c,

title = "Postexposure Efficacy of Recombinant Vesicular Stomatitis Virus Vectors Against High and Low Doses of Marburg Virus Variant Angola in Nonhuman Primates",

abstract = "A recombinant vesicular stomatitis virus (rVSV) expressing the Marburg virus (MARV) Musoke variant glycoprotein fully protects macaques against 2 MARV variants and Ravn virus as a preventive vaccine and MARV variant Musoke as a postexposure treatment. To evaluate postexposure efficacy against the most pathogenic MARV variant, Angola, we engineered rVSVs expressing homologous Angola glycoprotein. Macaques were challenged with high or low doses of variant Angola and treated 20-30 minutes after exposure. A total of 25% and 60%-75% of treated macaques survived the high-dose and low-dose challenges, respectively. The more rapid disease progression of variant Angola versus variant Musoke may account for the incomplete protection observed.",

keywords = "Angola, Marburg virus, Musoke, filovirus, recombinant vesicular stomatitis virus, treatment., vaccine",

author = "Courtney Woolsey and Geisbert, {Joan B.} and Demetrius Matassov and Agans, {Krystle N.} and Viktoriya Borisevich and Cross, {Robert W.} and Deer, {Daniel J.} and Fenton, {Karla A.} and Eldridge, {John H.} and Mire, {Chad E.} and Geisbert, {Thomas W.}",

note = "Publisher Copyright: {\textcopyright} 2018. This article contains public sector information licensed under the Open Government Licence v3.0.",

year = "2018",

month = nov,

day = "22",

doi = "10.1093/infdis/jiy293",

language = "English (US)",

volume = "218",

pages = "S582--S587",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - Postexposure Efficacy of Recombinant Vesicular Stomatitis Virus Vectors Against High and Low Doses of Marburg Virus Variant Angola in Nonhuman Primates

AU - Woolsey, Courtney

AU - Geisbert, Joan B.

AU - Matassov, Demetrius

AU - Agans, Krystle N.

AU - Borisevich, Viktoriya

AU - Cross, Robert W.

AU - Deer, Daniel J.

AU - Fenton, Karla A.

AU - Eldridge, John H.

AU - Mire, Chad E.

AU - Geisbert, Thomas W.

PY - 2018/11/22

Y1 - 2018/11/22

N2 - A recombinant vesicular stomatitis virus (rVSV) expressing the Marburg virus (MARV) Musoke variant glycoprotein fully protects macaques against 2 MARV variants and Ravn virus as a preventive vaccine and MARV variant Musoke as a postexposure treatment. To evaluate postexposure efficacy against the most pathogenic MARV variant, Angola, we engineered rVSVs expressing homologous Angola glycoprotein. Macaques were challenged with high or low doses of variant Angola and treated 20-30 minutes after exposure. A total of 25% and 60%-75% of treated macaques survived the high-dose and low-dose challenges, respectively. The more rapid disease progression of variant Angola versus variant Musoke may account for the incomplete protection observed.

AB - A recombinant vesicular stomatitis virus (rVSV) expressing the Marburg virus (MARV) Musoke variant glycoprotein fully protects macaques against 2 MARV variants and Ravn virus as a preventive vaccine and MARV variant Musoke as a postexposure treatment. To evaluate postexposure efficacy against the most pathogenic MARV variant, Angola, we engineered rVSVs expressing homologous Angola glycoprotein. Macaques were challenged with high or low doses of variant Angola and treated 20-30 minutes after exposure. A total of 25% and 60%-75% of treated macaques survived the high-dose and low-dose challenges, respectively. The more rapid disease progression of variant Angola versus variant Musoke may account for the incomplete protection observed.

KW - Angola

KW - Marburg virus

KW - Musoke

KW - filovirus

KW - recombinant vesicular stomatitis virus

KW - treatment.

KW - vaccine

UR - http://www.scopus.com/inward/record.url?scp=85057168552&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057168552&partnerID=8YFLogxK

U2 - 10.1093/infdis/jiy293

DO - 10.1093/infdis/jiy293

M3 - Article

C2 - 29939296

AN - SCOPUS:85057168552

SN - 0022-1899

VL - 218

SP - S582-S587

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

ER -

Postexposure Efficacy of Recombinant Vesicular Stomatitis Virus Vectors Against High and Low Doses of Marburg Virus Variant Angola in Nonhuman Primates

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this